{"filing":{"accession_number":"0001171843-26-004333","cik":"0000882796","ticker":"BCRX","company_name":"BIOCRYST PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"f8k_062926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/f8k_062926.htm"},"events":[{"id":14452,"run_id":12865,"accession_number":"0001171843-26-004333","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"BioCryst's Board approved a plan on June 25, 2026 to discontinue internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence facility by end of 2026, involving employee termination benefits, severance, and a strategic shift toward external innovation. The restructuring resulted in improved 2026 non-GAAP operating expense guidance from $450–$470M to $420–$440M.","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11892,"accession_number":"0001171843-26-004333","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"BioCryst's Board approved a plan on June 25, 2026 to discontinue internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence facility by end of 2026. The disclosure explicitly identifies costs including \"employee termination benefits and severance\" as part of the restructuring plan. This is a material operational restructuring involving workforce reduction, facility closure, and associated exit costs—the core elements of Item 2.05 disclosure. The press release reinforces this as a strategic shift away from internal discovery toward external innovation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:07:40.150357+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11893,"accession_number":"0001171843-26-004333","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BioCryst announced a strategic restructuring involving discontinuation of internal discovery programs and closure of its Birmingham research facility by end of 2026, coupled with a shift to external innovation. While this includes workforce reduction elements, the disclosure centers on a material strategic business decision and operational restructuring rather than a specific workforce reduction charge. The company also improved 2026 non-GAAP operating expense guidance from $450–$470M to $420–$440M as a result, reflecting the operational impact of this strategic pivot.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:07:40.150357+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11892,"accession_number":"0001171843-26-004333","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"BioCryst's Board approved a plan on June 25, 2026 to discontinue internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence facility by end of 2026. The disclosure explicitly identifies costs including \"employee termination benefits and severance\" as part of the restructuring plan. This is a material operational restructuring involving workforce reduction, facility closure, and associated exit costs—the core elements of Item 2.05 disclosure. The press release reinforces this as a strategic shift away from internal discovery toward external innovation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:07:40.150357+00:00","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-06-29"},{"id":11893,"accession_number":"0001171843-26-004333","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BioCryst announced a strategic restructuring involving discontinuation of internal discovery programs and closure of its Birmingham research facility by end of 2026, coupled with a shift to external innovation. While this includes workforce reduction elements, the disclosure centers on a material strategic business decision and operational restructuring rather than a specific workforce reduction charge. The company also improved 2026 non-GAAP operating expense guidance from $450–$470M to $420–$440M as a result, reflecting the operational impact of this strategic pivot.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:07:40.150357+00:00","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-06-29"}]}